We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.185 | 0.17 | 0.20 | - | 163,557 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -859k | -0.0012 | -1.50 | 1.34M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/12/2019 12:17 | Looks ready to surge again | dm2000 | |
24/12/2019 12:04 | https://www.voxmarke | shanur90 | |
24/12/2019 11:51 | Laters Jaknife.... much laters. Since you don't like it you won't be posting here anymore no? | soupdragon55 | |
24/12/2019 11:51 | Sounds like lots of great things to come and payment anytime between now and the end of January Thanks for the link | dm2000 | |
24/12/2019 11:41 | Dan on Vox this morning at 37mins 50secs | soupdragon55 | |
24/12/2019 11:25 | Good tweethttps://mobile. | shanur90 | |
24/12/2019 11:23 | Merry Christmas everybody and lot's of profit for 2020 | galaxy enforcer | |
24/12/2019 11:23 | C’mon ye boy ye! | volsung | |
24/12/2019 10:51 | halfpenny, learn to read financials then come and talk. | soupdragon55 | |
24/12/2019 10:20 | Thanks cottoner......financ | meijiman | |
24/12/2019 10:17 | Roger Jones, Financial Controller and Company Secretary Roger has been a Fellow of the ACCA for more than 30 years. He has held a number of senior financial positions and key roles in life science companies including Cambridge Antibody Technology, Onyvax and two AIM-listed companies, Angel Biotechnology Holdings PLC and Physiomics PLC. Roger specializes in early-stage and growing companies and has a deep understanding of the financial issues faced by fast-growth, technology-led companies. Roger is highly experienced at implementing strong and reliable financial reporting, business planning, cash flow management and budgeting procedures. He is also an experienced Company Secretary. | cottoner | |
24/12/2019 10:15 | No , you need to take some perhaps. :-) edit - reply to halfpenny. | cottoner | |
24/12/2019 10:14 | Who is the FD at this company..is there one? | meijiman | |
24/12/2019 10:14 | Hmmmm are these guys taking drugs??? Read their latest RNS.. Half Year Overview The Group operates in the field of complex scientific research, specifically drug development through the use of cocrystallisation. H1 2020 was a year of progress. HAVE YOU SPOTTED THE ERROR?? 2020 has not happened yet!!!!! | halfpenny | |
24/12/2019 10:13 | All aboard | chinadog3 | |
24/12/2019 10:07 | What's the inside spread ? | amaretto1 | |
24/12/2019 10:03 | Results seem to reflect exactly what has been released in the various interviews I've seen over last few months. Dr Gooding and the board appear to be open and up front with regards to progress being made.No nasty surprises and alot of potential.The thing I like most is that the board are invested and therefore in the same boat as the shareholders. No massive corporate salaries and small holdings so we know they have an interest in seeing the capital value grow.The only shame is that the Chinese (for whatever reason) have witheld payment and therefore cast a shadow over the NXP001 deal. Hopefully they can resolve this and draw a line under it in the next few months. This would obviously need to involve some kind of payment of the amount owed. I would be very sceptical of just an extension and further promises of an increased payment. It would also be interesting to know more about the reason why the CFO suddenly departed in September. This remains a mystery to me. | for fx sake | |
24/12/2019 10:03 | Nuformix has received written confirmation of Newsummit Biopharma's intention to pay the amounts owed as part of ongoing discussions to extend its working relationship with the Group. Nuformix continues to explore additional development opportunities within oncology supportive care programmes with discussions at an early stage with additional development partners. | dm2000 | |
24/12/2019 09:24 | Remember this stock was around 2p at the start of the year. Dan and the company have had a stellar year, congratulations to them! The future looks exciting to me, so I have them in my Sipp and ISA (long term holding) and I trade them as well Just because they are not up every day, should not detract from how well they are doing | excelsior | |
24/12/2019 09:12 | Happy holding through 2020 + Same with (MSYS), which is reacting well to a inverted h&s technical chart formation, another one to tuck away for the 20’s | ny boy | |
24/12/2019 09:02 | Some of you chaps need to refresh your reading skills. These are half year results to Sept 2019. So to the poster above who seems to think that cash in hand includes placing money. No it falls in Half 2 and is not relevant to a Half 1 interim report. These are good results set against a promised 'promising' H2 which btw is already half way through. Happy Christmas | chinadog3 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions